The tool will allow users to sift through three-dimensional images, such as synapses or neurons, more efficiently and comprehensively than previous technology allowed.
With the porcine epidemic diarrhea virus wiping out some 100,000 piglets a week, animal health company VMRD has developed a diagnostic tool that can be used to detect antibody to the virus.
Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.
The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma.
As the death toll from West Africa's Ebola outbreak hits nearly 540--a 60% mortality rate--drug development for the untreatable disease is lagging, largely due to lack of interest from Big Pharma and the relative infrequency of the disease.
Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.
Translational medicine, which bridges the science of the emerging preclinical portfolio and the early development space where molecules are studied in humans for the first time, is an important if not essential element of successful pharmaceutical development.
If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data that has just been posted on dupilumab for severe eczema.
Gynesonics has raised an additional $6 million in its march toward raising a total round of $35.5 million in equity and debt, according to an SEC filing. The additional cash is timely, coming on the heels of its receipt of a European CE mark for and treatment of the first patient with its next-generation VizAblate System in June.
Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd be much better off if they spurned Valeant's offer to buy the company and gut its R&D division. Citing sources close to the company, Bloomberg is reporting that the cutbacks should include work on its most "unpromising" programs in the pipeline.